Mechanistic investigation into the selective anticancer cytotoxicity and immune system response of surface-functionalised, dichloroacetate-loaded, UiO-66 nanoparticles.
ABSTRACT
The high drug loading and excellent biocompatibilities of metal-organic frameworks (MOFs) have led to their application as drug delivery systems (DDSs). Nanoparticle surface chemistry dominates both biostability and dispersion of DDSs while governing their interactions with biological systems, cellular and/or tissue targeting, and cellular internalisation, leading to a requirement for versatile and reproducible surface functionalisation protocols. Herein, we explore not only the effect of introducing different surface functionality to the biocompatible Zr-MOF UiO-66, but also the efficacy of three surface modification protocols: (i) direct attachment of biomolecules (folic acid, biotin) introduced as modulators of UiO-66 synthetic, (ii) our previously reported ''click-modulation" approach to covalently attach polymers (poly(ethylene glycol), poly-L-lactide, poly-Nisopropylacrylamide) to the surface of UiO-66 through click chemistry, and (iii) surface ligand exchange, to postsynthetically coordinate folic acid, biotin and heparin to UiO-66. The innovative use of a small molecule with metabolic anticancer activity, dichloroacetic acid (DCA), as a modulator during synthesis is described, and found to be compatible with all three protocols, yielding surface-coated, DCA-loaded (10-20% w/w) nanoMOFs (70-170 nm) .
External surface modification generally enhances stability and colloidal dispersion of UiO-66.
Cellular internalisation routes and efficiencies of UiO-66 by HeLa cervical cancer cells can be tuned by surface chemistry, and anticancer cytotoxicity of DCA-loaded MOFs correlates with endocytosis efficiency and mechanisms. The MOFs with the most promising coatings (folic acid, poly(ethylene glycol), poly-L-lactide, and poly-N-isopropylacrylamide) were extensively tested for selectivity of anticancer cytotoxicity against MCF-7 breast cancer cells and HEK293 healthy kidney cells, as well as for cell proliferation and ROS production against J774 macrophages and peripheral blood lymphocytes (PBLs) isolated from the blood of human donors. DCA-loaded, folic acid modified UiO-66 selectively kills cancer cells without harming healthy ones or provoking immune system response in vitro, suggesting a significant targeting effect and great potential in anticancer drug delivery. The results provide mechanistic insight into the design and functionalisation of MOFs for drug delivery, and underline the availability of various in vitro techniques to potentially minimise early-stage in vivo animal studies, following the three Rs: reduction, refinement and replacement.
INTRODUCTION
Drug delivery systems (DDSs) have become an exciting alternative to conventional treatments for many diseases, such as cancer, as they have the potential to reduce unwanted side effects while maximizing treatment efficiency. 1 Several strategies have been studied, but the application of DDSs is often limited by bioavailability, 2 uncontrolled release of the drug (i.e. the burst effect), 3 poor loading capacity, 4 toxicity 5 and inefficient cellular internalisation. 6 Among them, metal-organic frameworks (MOFs) 7 hybrid, highly porous crystalline structures composed of metal clusters linked by multidentate organic ligandsoffer several advantages compared to available DDSs, as they combine desirable features of both organic (biocompatibility) and inorganic (high loadings) systems. [8] [9] [10] Surface modifications of DDSs can minimize their interaction with the bulk, improving stability and dispersion, 11 and allowing them to cross physiological barriers, 12 providing the possibility of targeted carriers. 13 They can also decrease immune system recognition. 10, 14 Despite the clear need to develop reproducible and versatile protocols to modify the outer surfaces of MOFs, few studies have addressed this issue so far, and even though it has been reported that drugs can be introduced into MOFs during synthesis, 15 achieving one potsyntheses to create drug containing nanoparticulate MOFs (NMOFs) with functionalised surface is still a challenging goal. Different approaches to functionalise the surfaces of MOFs have been reported, 16 which can be categorised into functionalisation during synthesis, by using the coordination modulation approach, 17 or through postsynthetic modification. [18] [19] [20] The Lewis acid character of MOFs' metal centres offers the possibility of coordinating nucleophiles to the coordinatively unsaturated metal sites available on the outer surface of NMOFs. In order to avoid inner surface functionalisation, this postsynthetic modification is usually achieved through size-selective protocols, where the functionality cannot penetrate the porosity. This approach was first reported by Rowe et al., 18 and since then has been applied by different groups. For example, histidine residues (his-tags), which contain imidazole groups, have been used to coordinate several peptides and proteins to three different MOFs surfaces: to the copper benzenetricarboxylate MOF, HKUST-1; to the ironfumarate MOF MIL-88A and to a related zirconium fumarate MOF. 19 Additionally, several polymer coatings, including oligonucleotides, have been added to the surfaces of MOFs by coordination to the metal clusters through one of the polymers' ends. [21] [22] [23] The well-known surface ligand exchange (SLE) protocolpostsynthetically exchanging surface ligands for desired functionalityis also based on coordination chemistry. 24 It is also important to mention that silica coating has been widely used to increase MOFs' water stability, induce slow release, and to attach surface reagents through the siloxane groups. 25 Although this approach can dramatically enhance some MOFs properties, drawbacks exist in the fact that the silica coating can block pore access, and that some silica nanoparticles have been found to be toxic. 26 Postsynthetic covalent modifications, performed on functionalised organic linkers, have been widely used in biological applications of NMOFs. 27 For example, Lin and co-workers postsynthetically attached a cisplatin prodrug to MIL-101-NH 2 amino group present in the MOF linker 28 They also utilised a cisplatin prodrug as the linker directly during synthesis, 25 followed by silica coating and subsequent targeting peptide attachment. Once again, to selectively functionalise the outer surface, a surface reagent bigger than the pore opening is required. Additionally, unsaturated carboxylic acid groups present on the MOF surface can also be exploited for postsynthetic covalent surface modifications. For example, a green fluorescent protein was coupled to surface carboxylate groups of different MOFs using a carbodiimide-mediated reaction, 29 and then the protocol was applied to couple PEG5000-NH 2 and Stp-10C, 20 a derived oligoamino amide with proton-sponge features. However, the low reactivity of the organic linker's carboxylates hinders the application of this protocol, resulting in very low surface coatings (1-2% w/w).
Interest in zirconium-based MOFs as DDSs is arising as a consequence of their high chemical stability compared to iron MOFs, 30 and their safe use has been validated in vitro 12, 23, [31] [32] [33] [34] [35] [36] [37] [38] [39] and in vivo, 40 showing almost no acute cytotoxicity, with efficient performance in anticancer drug delivery. In particular, the zirconium terephthalate MOF UiO-66 (UiO standing for Universitetet i Oslo) has excellent biocompatibility 40 which, together with its wellknown structure and characterisation, 41 ability to cross the cell membrane 33, 36 and pH responsive drug release, 35, 36 makes it a great candidate for nanoparticle-conjugated anticancer drug delivery. Additionally, it is well known that monocarboxylic acid functionalised modulators can be attached to its surface and defect sites during synthesis, yielding highly porous nanoparticles. 42 We have previously reported the ''click modulation'' protocol for UiO-66, 32 in which we introduced functionalised modulators (p-azidomethylbenzoic acid, L1 and ppropargyloxybenzoic acid, L2, Fig 1) to UiO-66 nanoparticle surfaces and defect sites during their synthetic process, followed by postsynthetic covalent conjugation of different surface functionality using copper(I)-catalysed azide-alkyne cycloaddition (CuAAC). Attaching protecting PEG2000 chains to the MOF surface enhanced stability in phosphate buffered saline (PBS) solutions, enabled pH-responsive cargo release and tuned UiO-66 cell uptake pathways from clathrin-mediated to the more desirable caveolae-mediated route, which allows particles to circumvent cargo degradation in the lysosomes. 36 The effect of surface chemistry on DDS efficiency was evident in the enhanced cytotoxicity of the anticancer drug, dichloroacetate (DCA), which can be loaded into the NMOF as a co-modulator (dichloroacetic acid) during synthesis. Only the PEGylated MOF enhanced the cytotoxicity of DCA towards HeLa cancer cells, likely as NMOFs internalised through caveolae-mediated endocytosis can escape the early endosome, resulting in cytosolic release of the cytotoxic cargo. using the functionalised modulators L1 and L2. 32 Note that in this study, UiO-66-L2 is prepared by surface ligand exchange from UiO-66-L1, and not through coordination modulation.
The need to find a rationalisation between the intrinsic characteristics of NMOFs, such as surface chemistry, and their therapeutic efficacy is inherently clear, providing if so the possibility of reducing animal testing while maximizing the potential application of MOFs as 
RESULTS AND DISCUSSION
Three different surface modification protocols were assessed: (i) direct incorporation of 
Synthesis and Characterisation
Coordination Modulation: UiO-66-L1 was synthesised (see Figure 2a for synthetic methodologies) following our previously reported coordination modulation solvothermal protocol. 32 The coordination modulation approach, first reported by Fisher and co-workers, 44 is based on the use of modulators with similar chemical functionality to the linker during the synthetic process. However, the modulators can play different roles during synthesis, in some occasions inducing defects (such as missing linkers or clusters) 42 as well as capping crystal surfaces. This approach can also be used for size control 45 These results show that L1 can be easily exchanged by L2and thus potentially other coordinating agentspostsynthetically on the outer surface of UiO-66-L1.
We subsequently used both folic acid and biotin as modulators in solvothermal syntheses of UiO-66 (SI, Section S3.2). The samples were named UiO-66-FA (CM) and UiO-66-Biot-AcOH (CM) to reflect that acetic acid was required as a co-modulator in the synthesis of the biotin-coated sample, where CM stands for coordination modulation to distinguish them from samples prepared by postsynthetic ligand exchange (Figure 2a ). The samples were crystalline and phase pure as confirmed by PXRD ( Figure 3a ). 1 H NMR spectra of acid digested samples of the NMOFs showed the presence of the functional modulator in both cases (28 mol % for folate and only 2 mol % for biotin, see Table 1 ), but no AcOH in UiO-66-Biot-AcOH (CM). The gravimetric folic acid content was also calculated by UV-Vis spectroscopy of acid digested UiO-66-FA (CM), and found to be 13.6% (w/w) Fourier transform infra-red (FT-IR) spectra showed appearance of modulator signals with slight shifts as a possible consequence of their coordination to the available zirconium units.
In concordance, thermogravimetric analysis (TGA) profiles showed new mass loss events starting at higher temperatures than the free modulators' thermal decomposition, strongly indicating their attachment, which was unequivocally confirmed by nitrogen adsorption and desorption isotherms, revealing highly porous samples. UiO-66-Biot-AcOH (CM) was more porouswith a BET area of 1377 m 2 g -1than UiO-66-FA (CM), which exhibited a BET area of 753 m 2 g -1 . This could be explained by the higher modulator content in UiO-66-FA (CM) and the likely poorer crystallinity and/or smaller particle size indicated by the broad Bragg peaks in the PXRD pattern. SEM (Figure 3b ) showed UiO-66-FA (CM) to have a homogeneous distribution of small nanoparticles (~50 nm), reflected in the broadening of its PXRD pattern, and indicating that folic acid is acting as a capping agent during UiO-66 synthesis. On the other hand, UiO-66-Biot-AcOH (CM) forms as well-defined nanoparticles around 150 nm in size. These results confirm that coordination modulation can be used to simultaneously control the surface chemistry and particle size of NMOFs. It has been previously reported that when the modulator is the only parameter varied during synthesis, particle size strongly correlates with the pK a of the modulator. 45 Our results also suggest that pK a influences modulator's attachment; the pK a values of the carboxylic acids of bdc are 3.54 and 4.46, while folic acid has pK a values of 3.5 and 4.3, biotin has a pK a of 4.5, and AcOH a pK a of 4.8, and therefore folic acid attachment is higher than biotin, while AcOH is not incorporated. Further, folic acid has two carboxylic acids in its structure while biotin has only one, and it has been reported that when coordinating histidine-conjugated peptides to a Zr-fumarate MOF, the binding affinity increases with the number of histidine residues. 19 and appearance of resonances assigned to folic acid, biotin and heparin. FT-IR spectra of the MOFs showed the disappearance of the azide band of L1 and the appearance of new vibration bands characteristic of the surface reagents, some of them slightly shifted, possibly as a consequence of coordination. TGA profiles of the functionalised samples showed new mass loss events, starting at a higher temperature than authentic samples of the coordinating agents, strongly suggesting attachment by coordination rather than simply surface adhesion. The metal residue (ZrO 2 ) at 800 °C was considerably lower than for their precursor sample UiO-66-L1, suggesting significant organic mass addition at the surfaces.
The fact that the samples retained porositywith BET areas between 870 and 950 m 2 g -1confirmed attachment to UiO-66 external surface without blocking the pores, although the slightly lower gravimetric surface areas are likely a consequence of the additional mass of the surface functionality.
Click Modulation: Propargyl-terminated poly-L-lactide and azide-terminated poly-Nisopropylacrylamide were attached to UiO-66-L1 and UiO-66-L2 respectively by CuAAC "click" chemistry using our previously reported click-modulation protocol, 32 (Figure 3b ), revealing a more rounded shape after surface coating compared to octahedral UiO-66-L1 nanoparticles, with the slight increase in particle size a consequence of the surface coating.
Stability and Dispersion of Surface Modified UiO-66
Our previous study showed that PEGylation enhanced the dispersion of UiO-66 in various solvents; unwanted aggregation could hinder cellular uptake and induce in vivo toxicity of DDSs. 32 Measurements performed in PBS again showed aggregation and precipitation of UiO-66-L1
and UiO-66-L2, while after surface coating, more stable dispersions were found (Figure 4a ). 
UiO

Endocytosis Efficiencies and Routes of Surface-Modified UiO-66
Calcein was selected as a fluorescent molecule to track the NMOFs inside cells, in order to study endocytosis pathways. 33 Calcein's hydrophilicity does not allow it to efficiently cross the cell membrane, and thus intracellular cytoplasmic fluorescence is significantly increased when calcein is incorporated into a carrier. 36 UiO-66-L1 and UiO-66-L2 were postsynthetically loaded with calcein following previously reported protocols, and their surfaces subsequently modified either using our click modulation method 32 (Table 2 ). HeLa cervical cancer cells (SI, Section S6.2). As all the cal@NMOF samples were prepared from the same base batch, we assume that variations are caused by changes in external surface chemistry, not particle size, in concert with our previous work which shows particle size has only minor effect until sizes >500 nm are reached. 34 Uptake efficiency was analysed after incubating cells with a fixed NMOF concentration (0.5 mgmL -1 ), normalising the data to UiO-66-L1 cell internalisation, taking into account differing calcein loading values ( Figure   5a ). (Table 2) . HeLa cells are known to over express the folate receptor (FR) on their surface, 47 and therefore the folate present on the surface of cal@UiO-66-FA (PS) could bind to the FR, providing a mode of targeting and enhanced internalisation of the NMOF by cells expressing FR.
To monitor the preferred routes of endocytosis, inhibitors were used to restrict uptake by certain pathways (SI, Section S6.3). 36 Chlorpromazine and sucrose were used to inhibit clathrin-mediated pathways although it is important to consider that sucrose can additionally inhibit some non-mediated endocytosis processes. Nystatin was used as an inhibitor of caveolae-mediated endocytosis and rottlerin was used to inhibit macropinocytosis. Both unfunctionalised cal@UiO-66 36 and cal@UiO-66-L1 32 have previously been shown to generally enter HeLa cells by clathrin-mediated endocytosis, while PEGylated cal@UiO-66-L1-PEG2000 showed caveolae-mediated endocytosis, 32 which is desirable for efficient treatment as the NMOF can potentially escape the early endosome, avoiding lysosome degradation and facilitating faster drug release in other cellular locations such as the cytosol. 48 When cells were incubated at 4 °C in order to decrease energy-dependent processes, such as endocytosis, cell internalisation of the NMOFs decreased by 50-85% compared to the control at 37° C (Figure 5b ). The only exception was cal@UiO-66-Biot (PS), where cell internalisation only decreased by 28%, confirming the observations from the previous uptake experiments that it is not efficiently internalised by HeLa cells (SI, Figure S66 ). As no efficient internalisation is observed, no further experiments were carried out with this sample.
Folate receptors have been reported to often be located within caveolae invaginations; 47 cal@UiO-66-FA (PS) uptake decreased to 62 ± 2% when HeLa cells were incubated with nystatin, a well-known caveolae-mediated endocytosis inhibitor, while no inhibition was found when incubated with chlorpromazine (clathrin-mediated inhibitor) (96 ± 3%), and only a minor effect (81 ± 5%) was observed when rottlerin was inhibiting macropinocytosis pathways. Sucrose significantly decreased cal@UiO-66-FA (PS) uptake to 36 ± 4%, meaning that folate coating not only provides a way of cancer targeting, but also alters cancer cell endocytosis selection pathways from clathrin-mediated to both caveolae- In the cases of cal@UiO-66-L1-PolyLact and cal@UiO-66-L2-PNIPAM, cell internalisation decreased when inhibiting with sucrose (50 ± 5% and 54 ± 1%, respectively), while no significant decrease was found when inhibiting clathrin-mediated (84 ± 11% and 105 ± 5% respectively) or caveolae-mediated routes (106 ± 13% and 103 ± 4% respectively), and only minor macropinocytosis attributions upon PNIPAM coating (80 ± 4%). These results indicate that these polymer-coated samples are mainly internalised by non-mediated endocytosis processes, with a significant contribution for cal@UiO-66-L1-PolyLact from energy independent processes.
Selectivity of Cytotoxicity of DCA-Loaded, Surface-Functionalised NMOFs
We previously reported the validity of the coordination modulation protocol to introduce a small molecule with high metabolic anticancer activity, dichloroacetate (DCA), 49, 50 as a modulator that is attached to UiO-66 metal nodes during synthesis. 32 DCA is a pyruvate dehydrogenase kinase (PDK) inhibitor which has been investigated for over 25 years for the treatment of mitochondrial disorders such as lactic acidosis. 51 PDK is one of the main enzymes responsible for promoting glycolysis over glucose oxidation in cancer cells, as it can inhibit pyruvate dehydrogenase (PDH), an enzyme that converts pyruvate to acetylCoA. 52 Once glucose has been transformed to pyruvate, instead of being decarboxylated to form acetylCoA and entering the Krebs cycle in the mitochondria, pyruvate is alternatively transformed to lactate in the cytosol of cancer cells, 53 allowing them to grow in hypoxic conditions (low presence of oxygen) and resist apoptosis. 54 DCA shifts cancer cells metabolism from glycolysis back to glucose oxidation by PDH re-activation, decreasing the mitochondrial membrane hyperpolarisation and activating Kv channels, thus unlocking cancer cells from a state of apoptosis resistance without affecting growth of healthy cells. 49, 50, 55 However, the hydrophilic nature of DCA means it does not efficiently cross the cell membrane 56 and thus free DCA displays low cytotoxicity, with IC 50 values in the milimolar range, three orders of magnitude lower than anticancer drugs such as cisplatin. 57 DCA is rapidly cleared out from the blood stream, with initial half-life times of about an hour, 58 leading to poor efficacy and targeting when the drug is injected alone. 55, 57 Nevertheless, cancer cells have shown remarkably lower resistance factors to DCA compared to cisplatin and other anticancer therapeutics, 57 which is a notable drawback for anticancer therapy.
Although DCA is not currently under clinical use as an anticancer drug, it has been studied as a potential metabolic cancer therapy since 2007, 49 with several clinical trials showing significant tumour remission without healthy cells damage, low side effects and toxicity, and safe chronic use. 59 However, due to its ability to cross the brain membrane barrier, chronic exposure to very high DCA doses can result in reversible peripheral neuropathy. 51 We have chosen DCA as the object of our study due to the fact that its cytotoxic effect will only be observed if MOFs are able to deliver cargo into the cytosol and subsequently reach the mitochondria. This allows experimental confirmation that therapeutically active DCA- Attaching a small molecule with anticancer activity to UiO-66 Zr positions during synthesis, creating defective structures, also allows the possibility of introducing a second drug into the MOF pores for multimodal treatments. For example, cisplatin prodrugs containing axial DCA ligands have been reported to be more effective than cisplatin, and able to overcome cisplatin resistance. 57 Similarly, DCA is known to enhance the anticancer effect of 5fluorouracil (5-FU) and to reduce resistance. 60 DCA@UiO-66, DCA@UiO-66-L1, and DCA@UiO-66-L2 were prepared (SI, Section S7.1) and found to be highly crystalline and phase pure, as determined by PXRD, with high DCA content, 15-20% (w/w), measured by both TGA and inductively coupled plasma mass spectrometry (ICP-MS) analysis (Table 1) . 1 H NMR spectroscopy showed incorporation of functionalised modulators incorporation (between 3 and 6 mol % compared to bdc) as well as DCA. Further characterisation of the samples' porosity showed that DCA is not stored in the pores, but attached to UiO-66 available zirconium positions, inducing defects and yielding highly porous nanoparticles of 70-170 nm in size, with BET areas between 1300 m 2 g -1 and 1540 m 2 g -1 , higher than unmodulated UiO-66. 41 In concordance, TGA profiles showed that DCA thermal decomposition occurs at a higher temperature than the one reported for the free drug, 61 and FT-IR profiles show shifting of the DCA carbonyl vibration band as a consequence of DCA coordination to available zirconium positions through its carboxylic acid group. During the preparation of this manuscript it was reported that the pK a of the modulator also affects the colloidal stability of MOFs, with the authors finding better colloidal dispersion for MOFs synthesised using modulators with lower pK a , as a consequence of the formation of defects and subsequent modulator incorporation. 62 Our own DCA-loaded samples were also found by DLS to be essentially monodisperse in water (SI, Figure S7 .8).
The use of folic acid or biotin with DCA as a co-modulator was also studied (SI, Scheme S2) to successfully introduce both a metabolically active anticancer molecule and more complex surface functionalities to UiO-66 structure in only one synthetic step (SI, Section S7.2). As with the above DCA@NMOFs, full characterisation of the samples through PXRD, 1 independently by TGA and ICP-MS, is given in Table 3 . In order to study the therapeutic efficacies of the folate coated NMOFs and assess the different methods of surface modification, we incubated HeLa cells with various concentrations of DCA@UiO-66-FA (PS), DCA 10 @UiO-66-FA 0.25 (CM) or DCA 5 @UiO-66-FA 1 (CM) for 72 h. Figure 6 shows the HeLa cell viability for the different NMOFs, normalized with an untreated control. We have previously shown that empty UiO-66 is not cytotoxic towards HeLa cells, 33 and although unfunctionalised DCA@UiO-66 also does not decrease HeLa cell proliferation (128 ± 5% cell viability at a concentration of 1 mgmL -1 ), likely as a consequence of inefficient cytosolic release after clathrin-mediated internalisation, all the folate-coated, DCA-loaded MOFs had decreased proliferation to a certain extent in a dose responsive manner (Figure 6a ). Interestingly, the postsynthetically coated DCA@UiO-66-FA (PS) was the least cytotoxic, with 74 ± 4% cell viability at a NMOF concentration of 1 mgmL -1 . Of the two samples prepared through coordination modulation, DCA 5 @UiO-66-FA 1 (CM), which has a higher folate content, was the most cytotoxic, with 14 ± 6% of cell proliferation at a NMOF concentration of 0.25 mgmL -1 and killing all cells (2 ± 1%) when incubated with 1 mgmL -1 of NMOF in growth media. DCA 10 @UiO-66-FA 0.25 (CM) started to reduce cell proliferation at 0.75 mgmL -1 (85 ± 3%) and only kills 52 ± 5% of cells at 1 mgmL -1 , despite containing more DCA (~19% w/w) than DCA 5 @UiO-66-FA 1 (CM) (~12% w/w). Clearly the mode of external surface attachment of folate is key to therapeutic activity: the most cytotoxic folate-coated MOF has the lowest drug content. The enhanced cytotoxicity may be due to folate coating enhancing endocytosis efficiency and promoting caveolae-mediated endocytosis, which we showed previously enhanced cytotoxicity of PEGylated UiO-66
loaded with DCA. 32 The postsynthetically coated MOF will have the bulk of the folic acid on the nanoparticle external surface, while the NMOFs prepared by coordination modulation may have folate throughout the nanoparticles in defect sites, enhancing the targeting properties even after the onset of degradation. Cytotoxicity of free DCA towards HeLa was found to be negligible until cells were incubated with concentrations >4 mgmL -1 (SI, Section S8.3) confirming that effective delivery of DCA into cells by the DDSs is occurring, with a greater than 300 fold enhancement in cytotoxicity compared to the free drug when DCA is transported into HeLa cells by DCA 5 @UiO-66-FA 1 (CM).
Interestingly, DCA@UiO-66-L1-PolyLact produced a similar effect on HeLa cell growth regardless of the incubation time, which could be indicative of its significant internalisation by energy-independent endocytosis, while empty UiO-66-L1-PolyLact did not show any toxicity.
Inhibition of cell growth starts to be observed when incubated with 0.75 mgmL -1 of DCAloaded MOF for 72 h (85 ± 3% cell viability), while it kills almost all HeLa cells at 1 mgmL -1 (Figure 6b ). Although the empty UiO-66-L2-PNIPAM was already found to be cytotoxic at concentrations of 0.5 mgmL -1 and above, DCA loading enhanced its cytotoxic effects, with
DCA@UiO-66-L2-PNIPAM killing all HeLa cells at the NMOF concentration of 0.25 mgmL -1 .
In contrast to folate coated NMOFs, although heparin coating resulted in enhanced endocytosis efficiency and partial uptake by caveolae-mediated endocytosis, no decrease in cell proliferation was found when HeLa cells were incubated with DCA@UiO-66-Hep for 72 h (Figure 6c ). UiO-66-Hep showed undesirable degradation kinetics and colloidal stability when compared to UiO-66 precursor samples, and so may not be suitably stable.
Additionally, the growth of three different colon cancer cell lines has been reported to be stimulated upon heparin addition, 63 , and a healthy kidney cell line (HEK293, standing for human embryonic kidney cells 293). We compared the cell viability with the DCA-loaded, unfunctionalised NMOF, DCA@UiO-66 (SI, Section S8.2). 64 We investigated the effect of the unfunctionalised DCA@UiO-66, which has the highest DCA content, against MCF-7 ( Figure 6d ) and HEK293 (Figure 6e ) cells, finding no negative effects on their viability, with 136 ± 4% and 212 ± 20% cell proliferation after 72 h of incubation with a solution of 1 mgml -1 of MOF compared to untreated controls. After 72 h of incubation, MCF-7 cell proliferation was drastically reduced when treated with DCA 5 @UiO-66-FA 1 (CM) (Figure 6d ). The dose-responsive curve showed a similar trend to the HeLa experiment, although with slightly lower efficacy; 71 ± 8% cell viability at a concentration of 0.5 mgmL -1 and 35 ± 8% for a concentration of 1 mgmL -1 . More importantly, after 72 h of incubation with HEK293 cells, proliferation was not reduced in the presence of DCA 5 @UiO-66-FA 1 (CM) at any concentration, with 107 ± 5% cell viability at the NMOF concentration of 1 mgmL -1 (Figure 6e ). These results suggest folate induces cancer cell-targeting, as HeLa cells have a higher FR overexpression than MCF-7, 65 and thus therapeutic efficacy in HeLa is more pronounced. On the other hand, HEK293 has been reported to have normal levels of expression of the FR, 66 and thus no effect is observed on their cell proliferation possibly as a consequence of poor internalisation and/or a lack of metabolic effect of DCA on healthy cells. It is also important to consider that free dichloroacetate was not cytotoxic to either DCA@UiO-66-L2-PNIPAM showed cytotoxicity for both, but more pronounced for MCF-7 (32 ± 8% viability) than for HEK293 (78 ± 14% viability) at 1 mgmL -1 . While the polymer coated, DCA loaded samples do show cytotoxicity towards MCF-7, the residual cytotoxicity towards HEK293 is a concern.
Our previous work with PEG-coated UiO-66 showed excellent cytotoxicity towards HeLa when loaded with DCA, and so the effect of polymer coating was further examined by determining the cytotoxicity of DCA@UiO-66-L1 and DCA@UiO-66-L1-PEG2000 towards MCF-7 and HEK293 cells. While DCA@UiO-66-L1 does not affect MCF-7 cell proliferation negatively, DCA@UiO-66-L1-PEG2000 induced some cytotoxicity with a 32 ± 3% cell proliferation during the same experiment, similar to the cell viability reported for HeLa cells (50 ± 3%) at the same concentration. 32 However, some unwanted cytotoxicity of DCA@UiO-66-L1-PEG2000 was observed against HEK293 (42 ± 6% viability) at the highest concentration of 1 mgml -1 , in contrast to DCA@UiO-66-L1.
In vitro Immune Response to DCA-Loaded NMOFs
The immune response toward exogenous materials plays a crucial role in any treatment efficacy; DDSs will not be efficient if they are cleared out of the blood stream by macrophages, or if they stimulate/suppress immune response or induce tissue damage 2 .
Cytotoxicity, uptake efficiency and reactive oxygen species (ROS) production by immune cells such as macrophages or lymphocytes are of great importance when considering the efficiency of a DDS, but, to the best of our knowledge, only few studies have assessed these issues with NMOFs to date. 14, 23, 67, 68 Importantly, it can provide further insights into possible treatment efficiency without resorting to early stage animal testing. In fact, cell proliferation was slightly enhanced (128 ± 10% and 142 ± 11%, respectively) at a NMOF concentration of 0.5 mgmL -1 . Similar results were obtained when a pool of PBLs was incubated with folate-coated NMOFs for 72 h, obtaining enhanced, dose-responsive cell proliferation by MTT assay for two independent experiments (one is plotted in Figure 7b , comparison available in SI) which showed similar trends. Viabilities of 295 ± 24% and 199 ± 34% for empty UiO-66-FA (CM) and 252 ± 28% and 146 ± 18% for DCA 5 @UiO-66-FA 1 (CM)
were found at 0.5 mgmL -1 incubation. 5% for the former, and 7 ± 2% and 3 ± 4% for the latter. These are major issues that may preclude the use of the polymer-coated samples in vivo.
The effect of the chemical constitution of the polymer chain was studied further by incubating J774 macrophages with our previously reported UiO-66-L1-PEG2000 and DCA@UiO-66-L1-PEG2000 materials, which decreased their cell proliferation to levels of 54 ± 1% and 70 ± 2%, respectively, at 0.5 mgmL -1 (Figure 7a ). In contrast, UiO-66-L1-PEG2000 and DCA@UiO-66-L1-PEG2000 induced PBL cell proliferation from a single pool to levels of 116 ± 12% and 128 ± 21% compared to untreated cells at a concentration of 0.5 mgmL -1 ( Figure   7b ). Whilst the response of the J774 cells and the HEK293 cells to DCA@UiO-66-L1-PEG2000 could be problematic, the selectivity of the cytotoxicity of folate targeted, DCA loaded, DCA 5 @UiO-66-FA 1 (CM) nanoparticles is very promising, killing almost all cancer cells whilst not negatively affecting the proliferation of healthy cells.
Reactive oxygen species (ROS) production was investigated to gain insights into the cytotoxic effects of the NMOFs and to assess induction of oxidative stress. 70 J774 macrophage cells and PBLs were incubated with different doses of the NMOFs over 2 h, followed by incubation with the intracellular fluorescent probe 2',7'-dichlorodihydrofluorescein diacetate (H2DC-FDA) in order to track ROS production by flow cytometry (SI, Section S9.3). DCA@UiO-66-L2-PNIPAM induced the highest ROS production in the J774 macrophages (Figure 7c) , with a 5.5 fold increase at a NMOF concentration of 0.5 mg mL -1 a possible reason for the significant cytotoxicity, while the non-cytotoxic empty UiO-66-L2-PNIPAM only induced a 1.4 fold increase in ROS production at the same concentration.
Whilst empty UiO-66-L1-PolyLact did not induce significant cytotoxicity in the J774 cell lines, higher ROS production was found when incubating macrophages with the empty sample (3.2 fold increase) compared to DCA@UiO-66-L1-PolyLact (1.9 fold increase), which is more cytotoxic. Similarly, incubating J774 macrophages with UiO-66-L1-PEG2000 induced a slightly higher ROS production (2 fold increase) than incubation with DCA@UiO-66-L1-PEG2000 (1.5 fold increase) for the same concentration. UiO-66-FA (CM) did not induce significant ROS production, with a 1.2 fold increase when incubating macrophages with a 0.5 mgmL -1 concentration of NMOF, while DCA 5 @UiO-66-FA 1 (CM) did induce ROS production with a 2.8 fold increase, although MTT assays showed cell proliferation was enhanced in all cases, suggesting that ROS production is not a major source of cytotoxicity for these particular MOFs. ROS production in PBLs was also monitored (SI, Section S9.3) with no discernible trends, although DCA 5 @UiO-66-FA 1 was again well tolerated. These results suggest that while higher concentrations MOFs can induce some ROS production, it does not seem to result in cytotoxicity towards these healthy cells. It is also important to note that concentrations of DCA-loaded NMOFs lower than 0.5 mgmL -1 did not induce considerable ROS production, despite being therapeutically active towards cancer cell lines.
CONCLUSIONS
In conclusion, we have assessed a number of different functionalities, as well as different surface modification protocolscoordination modulation, postsynthetic exchange, and covalent click modulationfor the surface functionalisation of UiO-66 nanoparticles for use in drug delivery. The use of carboxylate-containing drug molecules as modulators for synthesis of UiO-66 nanoparticles, in this study the anticancer metabolic target dichloroacetic acid, has been shown to be an efficient methodology to ensure high cargo loading at defect sites in one-pot syntheses that are also compatible with all the surface modification protocols. DCA modulation in particular generates colloidally-stable nanoparticles with high DCA-loading values that are amenable to further functionalisation without compromising porosity.
In nearly all cases, surface functionalisation enhances properties such as colloidal dispersion and stability towards phosphate-induced degradation compared to bare UiO-66.
Internalisation by HeLa cells is enhancedapart from biotin-coated samplesand certain surface coatings tune internalisation pathways to more desirable uptake routes, such as caveolae-mediated endocytosis, which may allow MOFs to escape the early endosome and result in increased cytosolic cargo release. Building on our preliminary results that show DCA@UiO-66-PEG2000 has enhanced cytotoxicity for HeLa as a consequence of its more These results demonstrate the power of surface functionalisation and importance of cell internalisation pathways in the application of MOFs for drug delivery. The potential of DCA 5 @UiO-66-FA 1 for use as a selective anticancer DDS for in vivo localised treatment is apparent, particularly given the use of the metabolic probe DCA as a modulator during synthesis resulting in a drug-loaded nanoparticle that is still porous and could be loaded with a second drug for synergistic multimodal therapy, 60 which we are currently investigating. The work also highlights the broad in vitro experimental toolkit available to provide information on cellular uptake, endocytosis mechanisms, immune response and cytotoxicity prior to any in vivo treatment, thus reducing the need for early stage animal testing and acting according to the three Rs: reduction, refinement and replacement.
